<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALTRETAMINE, HEXAMETHYLMELAMINE</span><br/>(al-tre'ta-meen)<br/><span class="topboxtradename">Hexalen<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Altretamine, formally hexamethylmelamine, is a synthetic cytotoxic antineoplastic drug. The mechanism of action is not clearly
         understood. Altretamine probably requires the liver enzyme system for activation of its cytotoxic properties.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Altretamine has demonstrated neoplastic activity in patients resistant to alkylating agents.</p>
<h1><a name="uses">Uses</a></h1>
<p>Ovarian cancer.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Breast, cervical, colon, endometrial, head, and neck cancer; small-cell lung cancers and lymphomas.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to altretamine, severe bone marrow depression, neurologic toxicity, pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ovarian Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 260 mg/m<sup>2</sup>/d for 14 or 21 consecutive d in a 28-d cycle<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give only under supervision of a qualified physician experienced in the use of antineoplastics.</li>
<li>Give in 4 divided doses after meals and at bedtime.</li>
<li>Discontinue altretamine for 14 d or longer and restart at 200 mg/m<sup>2</sup>/d if any of the following occur: severe GI intolerance; WBC count 3, granulocyte count 3; or progressive neurotoxicity.
         </li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Paresthesias, hyporeflexia, muscle weakness, peripheral numbness, ataxia, Parkinson-like tremors</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting</span>. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Leukopenia, thrombocytopenia</span>. <span class="typehead">Urogenital:</span> Slight increase in serum creatinine. <span class="typehead">Skin:</span> Alopecia and eczema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concomitant administration of altretamine and <span class="classification">tricyclic antidepressants</span> (<b>imipramine,</b>
<b>amitriptyline</b>), <span class="classification">monoamine oxidase inhibitors</span>, or <b>selegiline</b> have been reported to result in incapacitating dizziness and syncopal episodes during the first week of altretamine treatment.
      Patients became asymptomatic 2496 h after discontinuing <span class="classification">antidepressants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. Approximately 25% reaches systemic circulation due to extensive hepatic first-pass metabolism. <span class="typehead">Metabolism:</span> Rapidly demethylated in the liver to 5 minor and 4 major metabolites. <span class="typehead">Elimination:</span> 62% of the dose is excreted in the urine in 24 h. A small amount of altretamine is excreted through the lungs. <span class="typehead">Half-Life:</span> 13 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor blood counts at least monthly and prior to each course of therapy.</li>
<li>Perform a neurologic examination regularly; question patient about the presence of: paresthesias, hypoesthesias, muscle weakness,
            peripheral numbness, ataxia, decreased sensations, and alterations in mood or consciousness.
         </li>
<li>Withhold medication if neurologic symptoms fail to resolve with dose reduction. Notify physician. </li>
<li>Monitor for nausea and vomiting, which are related to the cumulative dose of altretamine. After several weeks some patients
            develop tolerance to the GI effects. Antiemetics may be required to control GI distress.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Taking altretamine after meals or with food or milk may decrease nausea.</li>
<li>Report symptoms indicative of neurotoxicity to physician (paresthesias, hypoesthesias, muscle weakness, peripheral numbness,
            ataxia, decreased sensations, and alterations in mood or consciousness).
         </li>
<li>
            							Note: GI, hematologic, and neurologic adverse effects may be severe.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>